XML 21 R5.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Total income and other revenues $ 2,237,215 $ 2,289,463 $ 2,122,353
Operating expenses      
Provision for changes in expected cash flows from financial royalty assets 904,244 452,842 230,839
Research and development funding expense 177,106 200,084 26,289
Amortization of intangible assets 5,670 22,996 23,058
General and administrative expenses 227,303 182,826 181,715
Financial royalty asset impairment 615,827 0 65,053
Total operating expenses, net 1,930,150 858,748 526,954
Operating income 307,065 1,430,715 1,595,399
Other expense/(income)      
Equity in losses/(earnings) of equity method investees 8,973 19,490 (44,459)
Interest expense 187,961 166,142 157,059
(Gains)/losses on derivative financial instruments (96,610) 21,532 42,076
Losses/(gains) on equity securities 33,442 48,066 (247,073)
Losses/(gains) on available for sale debt securities 6,815 (17,859) (18,600)
Interest income (78,335) (53,535) (28,379)
Other non-operating expense, net 14,755 5,678 32,821
Total other expenses/(income), net 77,001 189,514 (106,555)
Consolidated net income before tax 230,064 1,241,201 1,701,954
Income tax expense 0 0 0
Consolidated net income 230,064 1,241,201 1,701,954
Net income attributable to non-controlling interests 187,232 621,473 726,914
Net income attributable to Royalty Pharma plc $ 42,832 $ 619,728 $ 975,040
Earnings per Class A ordinary share      
Basic (in dollars per share) [1] $ 0.10 $ 1.49 $ 1.32
Diluted (in dollars per share) [1] $ 0.10 $ 1.49 $ 1.32
Weighted average Class A ordinary shares outstanding      
Basic (in shares) [1] 437,963 414,794 375,444
Diluted (in shares) [1] 437,972 414,802 375,455
Income from financial royalty assets      
Total income and other revenues $ 2,125,096 $ 2,065,083 $ 1,959,975
Revenue from intangible royalty assets      
Total income and other revenues 37,484 171,248 143,382
Other royalty income      
Total income and other revenues $ 74,635 $ 53,132 $ 18,996
[1] In 2020, amounts represents earnings per Class A ordinary share and weighted average Class A ordinary shares outstanding for the period from June 16, 2020 through December 31, 2020 following our initial public offering (“IPO”). See Note 13–Earnings per Share.